See more : Mytrex Health Technologies, Inc. (4431.TWO) Income Statement Analysis – Financial Results
Complete financial analysis of Quantum-Si incorporated (QSI) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Quantum-Si incorporated, a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Intrance Co.,Ltd. (3237.T) Income Statement Analysis – Financial Results
- Amundi S.A. (AMDUF) Income Statement Analysis – Financial Results
- IceCure Medical Ltd (ICCM.TA) Income Statement Analysis – Financial Results
- ZTO Express (Cayman) Inc. (2057.HK) Income Statement Analysis – Financial Results
- Datable Technology Corporation (TTMZF) Income Statement Analysis – Financial Results
Quantum-Si incorporated (QSI)
About Quantum-Si incorporated
Quantum-Si incorporated, a life sciences company, develops a single molecule detection platform for sample preparation and sequencing. It offers a proprietary single molecule detection platform for use in semiconductor industry to field proteomics to enable next generation protein sequencing. The company was incorporated in 2013 is based in Guilford, Connecticut.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 1.08M | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 594.00K | 2.58M | 1.04M | 894.00K | 0.00 |
| Gross Profit | 488.00K | -2.58M | -1.04M | -894.00K | 0.00 |
| Gross Profit Ratio | 45.10% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 67.03M | 72.06M | 46.58M | 27.56M | 28.10M |
| General & Administrative | 42.81M | 42.29M | 46.38M | 7.98M | 7.88M |
| Selling & Marketing | 400.00K | 7.00K | 3.96M | 1.15M | 634.00K |
| SG&A | 44.63M | 42.30M | 50.33M | 9.14M | 8.52M |
| Other Expenses | 0.00 | -20.15M | -5.00M | -10.00K | 5.00K |
| Operating Expenses | 111.66M | 114.36M | 96.91M | 36.69M | 36.62M |
| Cost & Expenses | 112.25M | 114.36M | 96.91M | 36.69M | 36.62M |
| Interest Income | 0.00 | 0.00 | 2.54M | 88.00K | 823.00K |
| Interest Expense | 0.00 | 0.00 | 5.00K | 9.00K | 0.00 |
| Depreciation & Amortization | 4.16M | 2.58M | 1.04M | 894.00K | 780.00K |
| EBITDA | -91.80M | -129.86M | -95.87M | -35.80M | -35.84M |
| EBITDA Ratio | -8,484.66% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -111.17M | -123.84M | -96.91M | -36.69M | -36.62M |
| Operating Income Ratio | -10,274.58% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 15.21M | -8.60M | 1.92M | 78.00K | 828.00K |
| Income Before Tax | -95.96M | -132.44M | -94.99M | -36.61M | -35.79M |
| Income Before Tax Ratio | -8,868.76% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 8.60M | -6.04M | -1.00K | 5.00K |
| Net Income | -95.96M | -141.04M | -88.95M | -36.61M | -35.80M |
| Net Income Ratio | -8,868.76% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.68 | -1.01 | -1.12 | -6.81 | -0.26 |
| EPS Diluted | -0.68 | -1.01 | -1.12 | -6.81 | -0.26 |
| Weighted Avg Shares Out | 141.30M | 139.26M | 79.58M | 5.38M | 136.40M |
| Weighted Avg Shares Out (Dil) | 141.30M | 139.26M | 79.58M | 5.38M | 136.40M |
Quantum-Si to Host Investor & Analyst Event in New York City on November 20th, 2024
BRANFORD, Conn.--(BUSINESS WIRE)--QSI announces Investor Day 2024.
Liberate Bio Integrates Quantum-Si's Next-Generation Protein Sequencing™ Platform to Enhance Gene Therapy Development
BRANFORD, Conn.--(BUSINESS WIRE)--Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing Company™, today announced that Liberate Bio, a Boston-based biotech unleashing the potential of genetic medicines with novel delivery vehicles, has integrated the Platinum® Next-Generation Protein Sequencer™...
Quantum-Si to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
BRANFORD, Conn.--(BUSINESS WIRE)--Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing CompanyTM, today announced that it will be participating in the 26th Annual H.C. Wainwright Global Investment Conference taking place in New York City September 9-11, 2024....
QuantumSi Incorporated (QSI) Upgraded to Buy: What Does It Mean for the Stock?
QuantumSi Incorporated (QSI) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Quantum-Si incorporated (QSI) Q2 2024 Earnings Call Transcript
Quantum-Si incorporated (NASDAQ:QSI ) Q2 2024 Earnings Call Transcript August 7, 2024 4:30 PM ET Company Participants Doug Farrell - VP, IR Jeff Hawkins - President and CEO Jeff Keyes - CFO Conference Call Participants Swayampakula Ramakanth - HCW Operator...
Quantum-Si Incorporated (QSI) Reports Q2 Loss, Lags Revenue Estimates
Quantum-Si Incorporated (QSI) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.21. This compares to loss of $0.18 per share a year ago.
3 Super-Cheap Penny Stocks for the Ultimate Speculator
In most circumstances, you should avoid extremely speculative ideas, especially those billed as cheap penny stocks. It's difficult to find hard statistics regarding the odds of success in this arena, in large part because of the diversity of enterprises and...
Quantum-Si Announces Presentation on the Use of Next-Generation Protein Sequencing™ to Detect Disease-Relevant Proteoforms at the Festival of Genomics and Biodata
BRANFORD, Conn.--(BUSINESS WIRE)--Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing Company™, today announced a presentation by Gloria Sheynkman, Ph.D., Assistant Professor in the Department of Molecular Physiology and Biological Physics at the University of Virginia at...
Quantum-Si Announces Presentations at ASMS and ESHG
BRANFORD, Conn.--(BUSINESS WIRE)--Quantum-Si Announces Presentations at ASMS and ESHG.
Quantum-Si Appoints Former Bio-Techne President and CEO, Chuck Kummeth, to serve as independent Chairman of the Board of Directors
BRANFORD, Conn.--(BUSINESS WIRE)--Quantum-Si Appoints Former Bio-Techne President and CEO, Chuck Kummeth, to serve as independent Chairman of the Board of Directors.
Source: https://incomestatements.info
Category: Stock Reports